Interestingly, patients with late-onset GBM more frequently exhibit chromosome 7 gain and chromosome 10 loss (7A10D; P = 0.012) as well as positive O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation (P = 0.043), while chromosome 1p/19q co-deletion, microsatellite stability, and tumor mutation burden remain comparable (Table S1 and Fig. 1D, E). Here, MGMT is linked to glioblastoma.